$26.00
$110.00
bear $26.00
base $67.00
bull $110.00
margin of safety $34.00
market price* $164.75
Business condition attached to the margin of safety
2+ consecutive full fiscal years of owner earnings (CFO-Capex-SBC) sustaining above roughly $3.50-4.00/share as CAE (final payments due 2029) and PWS/PFAS settlement (payments through 2036, front-loaded) cash outflows visibly decelerate, confirming the base-case recovery path rather than a renewed or enlarged litigation drag.
3M spun off its Health Care business (Solventum) on April 1, 2024; the 10-K confirms cash-flow statements through that date consolidate Solventum, so FY2015-2023 owner-earnings figures (which ran roughly $7-11/share on CFO-Capex-SBC) describe a larger, different enterprise than today's standalone 3M and are used only as legacy business-quality context, not as the growth base, per spinoff-entity convention. The real story is litigation cash timing: 3M booked $10.3B (PFAS/PWS) and $4.2B (Combat Arms Earplugs) charges to the P&L in 2023 as non-cash accruals (which is why 2023 CFO was actually elevated to $6.68B despite a $7.0B GAAP net loss), then in 2024-2025 those liabilities were paid down in cash (CFO reconciliation's 'Other net' line swung to -$5.4B and -$3.1B respectively), crushing reported CFO to $1.82B (2024) and $2.31B (2025) even though continuing-operations diluted EPS held at $6-7/share. Post-spin owner earnings (CFO-Capex-SBC) were $0.63/share (2024), $2.16/share (2025), and an annualized ~$3.80/share run-rate through 2026 H1 - a clear recovery as CAE payments (capped at $6.0B, running through 2029) and PWS/PFAS payments ($10.5-12.5B, running through 2036 but front-loaded) taper. Using a $1.9B 2026 owner-earnings run-rate as the base, a two-stage 10-year DCF plus Gordon terminal value, net debt of ~$9.6B (Q2 2026: $12.55B total debt less $2.96B cash) against 522.4M diluted shares yields bear $26 (4.0% growth/11.5% discount/2.0% terminal - litigation drag persists longer than expected), base $67 (8.8% growth/9.5% discount/2.5% terminal - CAE/PWS payments taper on schedule, earnings power normalizes toward the ~$6-7/share continuing-ops EPS run-rate), and bull $110 (11.5% growth/8.5% discount/2.75% terminal - faster litigation resolution plus margin recovery). The wide bear-bull spread, thin post-charge book equity ($2.95B), elevated leverage, real remaining legal tail risk (AFFF/personal-injury and non-US PFAS suits outside the PWS class settlement), and only about two years of clean standalone post-spin data justify a ~49% discount to base for the margin-of-safety price ($34, anchored near the bear case) rather than a flat 30% haircut. Current price of $179 sits above even the bull case, implying the market is pricing 3M off recovering EPS rather than the litigation-cash-adjusted owner earnings a conservative approach demands.